A recent study from UC San Francisco (UCSF) has shed light on the potential benefits of hormone therapy for postmenopausal women with multiple sclerosis. The study found that 75% of MS patients are women, and these women often experience slowed walking and fine motor changes during the postmenopausal period.
According to investigators, hormonal changes during menopause may accelerate MS progression, particularly in terms of walking and fine motor skills. However, the study suggests that hormone therapy may help mitigate this effect. The researchers observed a significant increase in data quality when compared to prior studies focused on Expanded Disability Status Scale (EDSS).
The study included 184 individuals with MS or clinically isolated syndrome using International Panel Criteria, and found that administration of systemic estrogen within 5 years of menopause was reported to determine hormone therapy use. Exclusion criteria included menopause caused by chemotherapy and amenorrheic status.
Clinician-derived EDSS scores were reported as the secondary outcome, indicating a significant deceleration of worsening after menopause, with a slope difference of 0.05. The study also found accelerated worsening of MS Functional Composite (MSFC) domains, including walking, fine motor, and cognitive skills.
However, due to low estrogen therapy use in participants, investigators could not reach a conclusion about its benefits. The researchers emphasized the need for large, randomized trials that compare hormone treatment to a placebo to determine its true effects on MS.
The study’s findings have significant implications for postmenopausal women with MS, highlighting the potential benefits of hormone therapy in mitigating symptoms and slowing disease progression.
Source: https://www.contemporaryobgyn.net/view/study-reports-accelerated-multiple-sclerosis-progression-at-menopause